ROYALTIES AND OTHER CONSIDERATION. 4.1 Within ninety (90) days after the pre-IND meeting to be held at the United States Food and Drug Administration (“FDA”) on December 13, 2005 (“The pre-IND Meeting”), the Company shall pay to Ovamed or directly to UIRF (at the Company’s option) the following:
Appears in 4 contracts
Samples: Exclusive Sublicense Agreement, Exclusive Sublicense Agreement (Coronado Biosciences Inc), Exclusive Sublicense Agreement (Coronado Biosciences Inc)